Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial.
Questions
1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to prevent recurrence? (00:16-01:30)
2. What was the rationale for investigating pembrolizumab in patients with high-risk stage II melanoma, in terms of previously demonstrated efficacy? (01:30-02:22)
3. Please outline the key objectives and methodology of the KEYNOTE-716 trial? (02:22-03:00)
4. What were the main efficacy and safety findings of the KEYNOTE-716 trial? (03:00-04:17)
5. How will these results impact the treatment of patients with high-risk stage II melanoma? (04:17-04:47)
Disclosures: Jason Luke has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
